Literature DB >> 11519288

Antiretroviral drugs in pediatrics.

C Rongkavilit1, B I Asmar.   

Abstract

The advent of potent drugs to treat HIV and the development of increasingly effective treatment strategies have resulted in dramatic improvements in the prognosis and quality of life for HIV-infected children. The purpose of this article is to provide the primary care physicians with practical information on antiretroviral drugs that are currently used for the treatment of pediatric HIV infection.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11519288     DOI： 10.1007/BF02752279

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   5.319


  21 in total

1.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  N Shaffer; R Chuachoowong; P A Mock; C Bhadrakom; W Siriwasin; N L Young; T Chotpitayasunondh; S Chearskul; A Roongpisuthipong; P Chinayon; J Karon; T D Mastro; R J Simonds
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Nov-Dec

3.  Efavirenz pregnancy warning.

Authors:  J Cadman
Journal:  GMHC Treat Issues       Date:  1998-03

4.  Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Authors:  S A Nachman; K Stanley; R Yogev; S Pelton; A Wiznia; S Lee; L Mofenson; S Fiscus; M Rathore; E Jimenez; W Borkowsky; J Pitt; M E Smith; B Wells; K McIntosh
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

5.  Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Authors:  P Krogstad; A Wiznia; K Luzuriaga; W Dankner; K Nielsen; M Gersten; B Kerr; A Hendricks; B Boczany; M Rosenberg; D Jung; S A Spector; Y Bryson
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

6.  Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed.

Authors:  W J Reiter; H Schön-Pernerstorfer; K Dorfinger; J Hofbauer; M Marberger
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

7.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

8.  Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.

Authors:  D C Watson; J J Farley
Journal:  Pediatr Infect Dis J       Date:  1999-08       Impact factor: 2.129

9.  Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.

Authors:  B Schmidt; K Korn; B Moschik; C Paatz; K Uberla; H Walter
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections.

Authors:  J W Cohen Stuart; W A Slieker; G T Rijkers; A Noest; C A Boucher; M H Suur; R de Boer; S P Geelen; H J Scherpbier; N G Hartwig; H Hooijkaas; M T Roos; B de Graeff-Meeder; R de Groot
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.